How much funding has Meiogenix raised?

Meiogenix has raised $13.0M in total funding, most recently a Series A round.

Who are Meiogenix's investors?

Meiogenix's investors include Sofinnova Partners, Genoa Ventures, Bpifrance, Casdin Capital.

Where is Meiogenix headquartered?

Meiogenix is headquartered in Durham, North Carolina, United States.

Meiogenix

Revolutionizing plant breeding for a sustainable future

Durham, United States · $13.0M raised

Biotech

Headquarters: Durham, North Carolina
Employees: 11–50
Business Model: B2B
Website: meiogenix.com

Total Funding: $13.0M
Last Round: $13.0M Series AMay 2022
Rounds: 1

About

Meiogenix is an agricultural biotechnology company developing AI-powered precision breeding technologies based on targeted chromosome recombination to accelerate crop improvement. By unlocking natural genetic diversity that traditional breeding methods cannot access, Meiogenix enables seed companies and plant breeders to deliver elite crop varieties with enhanced disease resistance, stress tolerance, and productivity. The company offers technology licensing partnerships and crop innovation programs for both specialty crops (tomato, fruits, vegetables) and major field crops (corn, rice, wheat, soybean). Meiogenix has US headquarters in Durham, North Carolina and offices in Paris, France.

Summary

Meiogenix is a Biotech company based in Durham, United States. It has raised $13.0M in total across 1 round, most recently a $13.0M Series A round in May 2022. Investors include Sofinnova Partners, Genoa Ventures and Bpifrance.